Your browser doesn't support javascript.
loading
Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease: US Multi-center Study.
Kim, Donghee; Adeniji, Nia; Latt, Nyann; Kumar, Sonal; Bloom, Patricia P; Aby, Elizabeth S; Perumalswami, Ponni; Roytman, Marina; Li, Michael; Vogel, Alexander S; Catana, Andreea M; Wegermann, Kara; Carr, Rotonya M; Aloman, Costica; Chen, Vincent L; Rabiee, Atoosa; Sadowski, Brett; Nguyen, Veronica; Dunn, Winston; Chavin, Kenneth D; Zhou, Kali; Lizaola-Mayo, Blanca; Moghe, Akshata; Debes, José; Lee, Tzu-Hao; Branch, Andrea D; Viveiros, Kathleen; Chan, Walter; Chascsa, David M; Kwo, Paul; Dhanasekaran, Renumathy.
Affiliation
  • Kim D; Stanford University, Stanford, California.
  • Adeniji N; Stanford University, Stanford, California.
  • Latt N; Ochsner Medical Center, New Orleans, Louisiana.
  • Kumar S; Weill Cornell Medicine, New York, New York.
  • Bloom PP; Massachusetts General Hospital, Boston, Massachusetts.
  • Aby ES; Hennepin County Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.
  • Perumalswami P; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Roytman M; University of California San Francisco, Fresno, California.
  • Li M; Brigham and Women's Hospital, Boston, Massachusetts.
  • Vogel AS; Brigham and Women's Hospital, Boston, Massachusetts.
  • Catana AM; Beth Israel Deaconess Medical Center, Boston, Massachusetts.
  • Wegermann K; Duke University, Durham, North Carolina.
  • Carr RM; University of Pennsylvania, Philadelphia, Pennsylvania.
  • Aloman C; Rush University Medical Center, Chicago, Illinois.
  • Chen VL; University of Michigan, Ann Arbor, Michigan.
  • Rabiee A; VA Medical Center, Washington, District of Columbia.
  • Sadowski B; Georgetown University, Washington, District of Columbia.
  • Nguyen V; University of Arizona/BannerHealth, Tucson, Arizona.
  • Dunn W; University of Kansas Medical Center, Kansas City, Kansas.
  • Chavin KD; University Hospitals Cleveland Medical Center, Cleveland, Ohio.
  • Zhou K; University of Southern California, Los Angeles, California.
  • Lizaola-Mayo B; Mayo Clinic, Scottsdale, Arizona.
  • Moghe A; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
  • Debes J; Hennepin County Medical Center, Minneapolis, Minnesota; University of Minnesota, Minneapolis, Minnesota.
  • Lee TH; Duke University, Durham, North Carolina.
  • Branch AD; Icahn School of Medicine at Mount Sinai, New York, New York.
  • Viveiros K; Brigham and Women's Hospital, Boston, Massachusetts.
  • Chan W; Brigham and Women's Hospital, Boston, Massachusetts.
  • Chascsa DM; Mayo Clinic, Scottsdale, Arizona.
  • Kwo P; Stanford University, Stanford, California.
  • Dhanasekaran R; Stanford University, Stanford, California. Electronic address: dhanaser@stanford.edu.
Clin Gastroenterol Hepatol ; 19(7): 1469-1479.e19, 2021 Jul.
Article in En | MEDLINE | ID: mdl-32950749
BACKGROUND & AIMS: Chronic liver disease (CLD) represents a major global health burden. We undertook this study to identify the factors associated with adverse outcomes in patients with CLD who acquire the novel coronavirus-2019 (COVID-19). METHODS: We conducted a multi-center, observational cohort study across 21 institutions in the United States (US) of adult patients with CLD and laboratory-confirmed diagnosis of COVID-19 between March 1, 2020 and May 30, 2020. We performed survival analysis to identify independent predictors of all-cause mortality and COVID-19 related mortality, and multivariate logistic regression to determine the risk of severe COVID-19 in patients with CLD. RESULTS: Of the 978 patients in our cohort, 867 patients (mean age 56.9 ± 14.5 years, 55% male) met inclusion criteria. The overall all-cause mortality was 14.0% (n = 121), and 61.7% (n = 535) had severe COVID-19. Patients presenting with diarrhea or nausea/vomiting were more likely to have severe COVID-19. The liver-specific factors associated with independent risk of higher overall mortality were alcohol-related liver disease (ALD) (hazard ratio [HR] 2.42, 95% confidence interval [CI] 1.29-4.55), decompensated cirrhosis (HR 2.91 [1.70-5.00]) and hepatocellular carcinoma (HCC) (HR 3.31 [1.53-7.16]). Other factors were increasing age, diabetes, hypertension, chronic obstructive pulmonary disease and current smoker. Hispanic ethnicity (odds ratio [OR] 2.33 [1.47-3.70]) and decompensated cirrhosis (OR 2.50 [1.20-5.21]) were independently associated with risk for severe COVID-19. CONCLUSIONS: The risk factors which predict higher overall mortality among patients with CLD and COVID-19 are ALD, decompensated cirrhosis and HCC. Hispanic ethnicity and decompensated cirrhosis are associated with severe COVID-19. Our results will enable risk stratification and personalization of the management of patients with CLD and COVID-19. Clinicaltrials.gov number NCT04439084.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / COVID-19 / COVID-19 Drug Treatment / Liver Cirrhosis / Liver Neoplasms Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / COVID-19 / COVID-19 Drug Treatment / Liver Cirrhosis / Liver Neoplasms Type of study: Clinical_trials / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Country/Region as subject: America do norte Language: En Journal: Clin Gastroenterol Hepatol Journal subject: GASTROENTEROLOGIA Year: 2021 Type: Article